Influence of the MBC/MIC ratio on the antibacterial activity of vancomycin versus linezolid against methicillin-resistant Staphylococcus aureus isolates in a pharmacodynamic model simulating serum and soft tissue interstitial fluid concentrations reported in diabetic patients

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 10, 2013, Pages 2291-2295

  Gonzalez, Natalia ^a   Sevillano, David ^a   Alou, Luis ^a   Cafini, Fabio ^a   Gimenez, Maria Jose ^a   Gomez Lus, Maria Luisa ^a   Prieto, Jose ^a   Aguilar, Lorenzo ^a  

^a SCHOOL OF MEDICINE   (Spain)

Author keywords

Diabetic foot infections; MRSA; Pharmacodynamic simulations; Tolerance

Indexed keywords

LINEZOLID; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BACILLUS SUBTILIS; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CALCULATION; COLONY FORMING UNIT; COMPUTER; CONTROLLED STUDY; DIABETIC FOOT; DIABETIC PATIENT; HUMAN; HUMAN TISSUE; INTERSTITIAL FLUID; LIMIT OF DETECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; SIMULATION; STAPHYLOCOCCUS AUREUS;

DIABETIC FOOT INFECTIONS; MRSA; PHARMACODYNAMIC SIMULATIONS; TOLERANCE;

ACETAMIDES; ANTI-BACTERIAL AGENTS; DIABETES MELLITUS; EXTRACELLULAR FLUID; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MODELS, THEORETICAL; OXAZOLIDINONES; SERUM; VANCOMYCIN;

EID: 84888802418     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt185     Document Type: Article

References (20)

1. Moran GJ, Krishnadasan A, Gorwitz RJ et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med 2006; 355: 666-74.
2. Aguilar L, Giménez MJ, Barberán J. Glycopeptide heteroresistance and tolerance in hospital gram-positive isolates: "invisible" phenomena to the clinician with clinical implications? (in Spanish). Rev Esp Quimioter 2009; 22: 173-9.
3. Sader HS, Jones RN, Rossi KL et al. Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals. J Antimicrob Chemother 2009; 64: 1024-8.
4. Majcher-Peszynska J, Haase G, Sass M et al. Pharmacokinetics and penetration of linezolid into inflamed soft tissue in diabetic foot infections. Eur J Clin Pharmacol 2008; 64: 1093-100.
5. Skhirtladze K, Hutschala D, Fleck T et al. Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery. Antimicrob Agents Chemother 2006; 50: 1372-5.
6. Stein GE, Schooley S, Peloquin CA et al. Linezolid tissue penetration and serum activity against strains of methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility in diabetic patients with foot infections. J Antimicrob Chemother 2007; 60: 819-23.
7. Walsh TR, Bolmström A, Qwärnström A et al. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin Microbiol 2001; 39: 2439-44.
8. González N, Aguilar L, Sevillano D et al. Efficacy of simulated cefditoren versus amoxicillin-clavulanate free concentrations in countering intrastrain ftsI gene diffusion in Haemophilus influenzae. Antimicrob Agents Chemother 2011; 55: 2788-94.
9. Traunmüller F, Schintler MV, Spendel S et al. Linezolid concentrations in infected soft tissue and bone following repetitive doses in diabetic patients with bacterial foot infections. Int J Antimicrob Agents 2010; 36: 84-6.
10. Andrews JM. Microbiological assays. In: Reeves DS, Wise R, Andrews JM et al. (eds). Clinical Antimicrobial Assays. 1st edn. Oxford: Oxford University Press, 1999; 35-44.
11. Sevillano D, Alou L, Cafini F et al. Prevalencia y perfil de sensibilidad de cepas de Staphylococcus aureus resistentes a meticilina (SARM) aisladas de úlceras de pie diabético. In: Abstracts of the Eleventh National Congress of the Spanish Society for Chemotherapy, Madrid, Spain, 2011. Abstract 79. http://www.seq.es/component/content/721?task=view (19 September 2012, date last accessed).
12. Rybak M, Lomaestro B, Rotschafer JC et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009; 66: 82-98.
13. Sader HS, Fritsche TR, Jones RN. Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin. Antimicrob Agents Chemother 2006; 50: 2330-6.
14. Traczewski MM, Katz BD, Steenbergen JN et al. Inhibitory and bactericidal activities of daptomycin, vancomycin, and teicoplanin against methicillin-resistant Staphylococcus aureus isolates collected from 1985 to 2007. Antimicrob Agents Chemother 2009; 53: 1735-8.
15. Jones RN. Key considerations in the treatment of complicated staphylococcal infections. Clin Microbiol Infect 2008; 14 Suppl 2: 3-9.
16. Jones RN. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis 2006; 42 Suppl 1: S13-24.
17. Gould IM. The problem with glycopeptides. Int J Antimicrob Agents 2007; 30: 1-3.
18. Docobo-Pérez F, López-Rojas R, Domínguez-Herrera J et al. Efficacy of linezolid versus a pharmacodynamically optimized vancomycin therapy in an experimental pneumonia model caused by methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 2012; 67: 1961-7.
19. Rayner CR, Forrest A, Meagher AK et al. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet 2003; 42: 1411-23.
20. Huang YT, Liao CH, Teng LJ et al. Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan. Clin Microbiol Infect 2008; 14: 124-9.